China Pioneer Pharma Holdings Ltd
HKEX:1345
Intrinsic Value
China Pioneer Pharma Holdings Ltd. is an investment holding company, which engages in the manufacture, promotion, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
China Pioneer Pharma Holdings Ltd
stock under the Base Case scenario is
2.03
HKD.
Compared to the current market price of 1.84 HKD,
China Pioneer Pharma Holdings Ltd
is
Undervalued by 10%.
China Pioneer Pharma Holdings Ltd's market capitalization is 2.3B HKD.
China Pioneer Pharma Holdings Ltd stock price is 1.84 HKD.
China Pioneer Pharma Holdings Ltd stock price (1.84 HKD) is 10% less than its Intrinsic Value (2.03 HKD).
China Pioneer Pharma Holdings Ltd stock price (1.84 HKD) is 6% less than its DCF Value (1.96 HKD). Open DCF Valuation
China Pioneer Pharma Holdings Ltd stock price (1.84 HKD) is 13% less than its Relative Value (2.11 HKD). Open Relative Valuation
China Pioneer Pharma Holdings Ltd has upside potential of 84% compared to the average analyst price target.
Open Wall St Estimates
China Pioneer Pharma Holdings Ltd has positive Net Income for the last twelve months.
China Pioneer Pharma Holdings Ltd's Revenue has grown by 1% over the past 12 months.
China Pioneer Pharma Holdings Ltd has positive Operating Income for the last twelve months.
China Pioneer Pharma Holdings Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
China Pioneer Pharma Holdings Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
China Pioneer Pharma Holdings Ltd's Revenue has been growing by 6% per year for the last 3 years.
China Pioneer Pharma Holdings Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 6% to 13%.
China Pioneer Pharma Holdings Ltd's ROE (Return on Equity) has increased in the last 3 years from 5% to 14%.
China Pioneer Pharma Holdings Ltd has positive three-year average ROE (Return on Equity): 16%. The company is efficient at transforming stockholders' equity into net income.
China Pioneer Pharma Holdings Ltd has positive three-year average ROIC (Return on Invested Capital): 16%. The company is efficient at using invested capital to generate operating income.
China Pioneer Pharma Holdings Ltd has positive Free Cash Flow for the last twelve months.
China Pioneer Pharma Holdings Ltd has negative Net Debt. This means that the company has more cash and short-term investments (124m CNY) than debt (73m CNY).
China Pioneer Pharma Holdings Ltd has positive Gross Profit for the last twelve months.
China Pioneer Pharma Holdings Ltd's short-term assets (1B CNY) exceed its short-term liabilties (443m CNY).
China Pioneer Pharma Holdings Ltd's long-term assets (2B CNY) exceed its long-term liabilties (524m CNY).
China Pioneer Pharma Holdings Ltd's D/E (Debt to Equity) is very low and is equal to 0.07.
China Pioneer Pharma Holdings Ltd's Altman Z-Score is very high and is equal to 5.37.
China Pioneer Pharma Holdings Ltd earns more than enough operating income (182m CNY) to safely cover interest payments on its debt (2m CNY).
Valuation Backtest
China Pioneer Pharma Holdings Ltd
Run backtest to discover the historical profit from buying and selling
China Pioneer Pharma Holdings Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
China Pioneer Pharma Holdings Ltd
Balance Sheet Decomposition
China Pioneer Pharma Holdings Ltd
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 124.4m |
| Receivables | 542.5m |
| Other Current Assets | 440m |
| Non-Current Assets | 424m |
| Long-Term Investments | 117.1m |
| PP&E | 268.2m |
| Intangibles | 36.4m |
| Other Non-Current Assets | 2.3m |
| Current Liabilities | 442.7m |
| Accounts Payable | 338.2m |
| Short-Term Debt | 60m |
| Other Current Liabilities | 44.5m |
| Non-Current Liabilities | 81.8m |
| Long-Term Debt | 12.7m |
| Other Non-Current Liabilities | 69m |
Earnings Waterfall
China Pioneer Pharma Holdings Ltd
|
Revenue
|
1.6B
CNY
|
|
Cost of Revenue
|
-898.4m
CNY
|
|
Gross Profit
|
668.2m
CNY
|
|
Operating Expenses
|
-486.7m
CNY
|
|
Operating Income
|
181.5m
CNY
|
|
Other Expenses
|
-35.8m
CNY
|
|
Net Income
|
145.7m
CNY
|
Free Cash Flow Analysis
China Pioneer Pharma Holdings Ltd
Profitability Score
Profitability Due Diligence
China Pioneer Pharma Holdings Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
China Pioneer Pharma Holdings Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
China Pioneer Pharma Holdings Ltd's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Score
China Pioneer Pharma Holdings Ltd's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
China Pioneer Pharma Holdings Ltd
According to Wall Street analysts, the average 1-year price target for
China Pioneer Pharma Holdings Ltd
is 3.39 HKD
.
Shareholder Return
Price
China Pioneer Pharma Holdings Ltd
| Average Annual Return | 48.83% |
| Standard Deviation of Annual Returns | 55.56% |
| Max Drawdown | -52% |
| Market Capitalization | 2.3B HKD |
| Shares Outstanding | 1 257 447 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
China Pioneer Pharma Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
China Pioneer Pharma Holdings Ltd. is an investment holding company, which engages in the manufacture, promotion, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 250 full-time employees. The company went IPO on 2013-11-05. The firm operates through two business segments. The Ophthalmic Pharmaceutical Products segment is engaged in the sales of ophthalmic pharmaceutical products by provision of channel management services and co-promotion services. The Products Sold Via the Provision of Comprehensive Marketing, Promotion and Channel Management Services segment is engaged in the sales of all pharmaceutical products and medical devices except for ophthalmic pharmaceutical products. The firm is also engaged in the manufacturing of chemical and pharmaceutical products through its subsidiaries.
Contact
IPO
Employees
Officers
The intrinsic value of one
China Pioneer Pharma Holdings Ltd
stock under the Base Case scenario is
2.03
HKD.
Compared to the current market price of 1.84 HKD,
China Pioneer Pharma Holdings Ltd
is
Undervalued by 10%.
You don't have any saved screeners yet
